New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTDO, TTWO, SLCA, TSRO, NEM, CPE, HP, PSMI, CACCOn the Fly: Analyst Downgrade Summary
Callon Petroleum (CPE) downgraded to Neutral from Buy at SunTrust... Credit Acceptance (CACC) downgraded to Market Perform from Outperform at JMP Securities... Helmerich & Payne (HP) downgraded to Underperform from Neutral at Credit Suisse... Newmont Mining (NEM) downgraded to Neutral from Overweight at JPMorgan... Peregrine (PSMI) downgraded to Neutral from Overweight at JPMorgan... U.S. Silica (SLCA) downgraded to Hold from Buy at Jefferies... Diamond Offshore (DO) downgraded to Hold from Buy at Wunderlich... TESARO (TSRO) downgraded at Morgan Stanley... Take-Two (TTWO) downgraded to Hold from Buy at Benchmark Co.
News For CPE;CACC;HP;NEM;PSMI;SLCA;DO;TSRO;TTWO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:38 EDTTSROFly Watch: Biotech sector events to watch for this summer
Three key events in the biotech sector are slated to occur this summer, Mizuho Securities previewed in a note to investors today. Namely, data from Clovis Oncology's (CLVS) lung cancer treatment is expected to be released, interim data for Verastem's (VSTM) cancer treatment could be unveiled and the PDUFA date for Tesaro's (TSO) rolapitant drug for chemotherapy-induced nausea and vomiting will occur. A PDUFA date is the day on which the FDA is expected to decide whether to approve a drug. WHAT'S NEW: Data for Clovis' rociletinib lung cancer treatment is expected by the firm to be released September 6-9, Mizuho analyst Peter Lawson wrote. Favorable data could result in the the drug more quickly becoming the first treatment option after it hits the market, the analyst stated. Interim data for Verastem's cancer treatment product, defactinib, will have one of three outcomes, Lawson forecast: additional patients will be enrolled in the study, the study will be terminated due to poor results or the patients in the study with low levels of a tumor suppressor gene product called Merlin will be enriched for Merlin. According to Lawson, expectations heading into the trial are low, and the most likely outcome is that the Merlin enrichment scenario will occur. If this scenario does occur, Verastem's stock will probably temporarily fall, potentially creating a better entry point, Lawson believes. The PDUFA date for Tesaro's rolapitant drug is September 5, the analyst stated. The analyst kept a $103 price target and Buy rating on Clovis, a $67 price target and Buy rating on Tesaro and a $21 price target and Buy rating on Verastem. PRICE ACTION In early trading, Clovis fell 2.2% to $83.98, Verastem retreated 2.3% to $6.96 and Tesaro dropped 1.7% to $55.80.
10:04 EDTHPHigh option volume stocks
Subscribe for More Information
09:35 EDTHPActive equity options trading on open
Active equity options trading on open: AAPL HP TSLA FB GRPN BP MEP GILD
June 29, 2015
08:22 EDTTSROTESARO appoints Jeffrey Hanke to Chief Scientific Officer
Subscribe for More Information
June 26, 2015
10:00 EDTTTWOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
June 25, 2015
16:53 EDTTTWOTake-Two initiated with a Buy at Mizuho
Subscribe for More Information
10:00 EDTCPEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:48 EDTCPECallon Petroleum initiated with a Buy at Wunderlich
Subscribe for More Information
June 24, 2015
10:36 EDTTTWOElectronic Arts advances after analysts positive on E3 showing
Subscribe for More Information
10:00 EDTTTWOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:44 EDTHPHelmerich & Payne now sees Q3 average rig revenue/day dropping to $26,500
Subscribe for More Information
07:19 EDTDOU.K. panel to decide on first fracking in area since 2011, WSJ reports
Subscribe for More Information
07:10 EDTTTWOTake-Two upgraded to Buy with $35 target at Jefferies
Subscribe for More Information
06:44 EDTTTWOTake-Two upgraded to Buy from Hold at Jefferies
Price target $35.
June 23, 2015
06:29 EDTNEMNewmont Mining reinstated with an Outperform at Credit Suisse
Target $30.
June 22, 2015
11:17 EDTHPHelmerich & Payne management to meet with Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use